THU0617 Work Productivity and Daily Activity in Patients with Rheumatoid Arthritis in Four Phase III Randomized Clinical Trials of Baricitinib. (15th July 2016)

• Record Type: Journal Article
• Authors: Smolen, J.S.; DeLozier, A.M.; de Bono, S.; Yang, L.; Gaich, C.
• Is Part Of: Annals of the rheumatic diseases. Volume 75(2016)Supplement 2
• Page Start: 416
• Page End: 416
• Publication Date: 2016-07-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2016-eular.1429
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, was efficacious in Ph 3 studies in patients (pts) with active RA. 1–4 Objectives: To assess effects of bari on workplace and daily activity with the Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire in adult RA pts. Methods: In 4 Ph 3 trials (table), pts completed the WPAI-RA at baseline and ∼every 4 wks. Least-squares mean (LSM) of change from baseline was compared with ANCOVA. Results: Across studies, bari pts tended to have less absenteeism, presenteeism, and impairment in work productivity and daily activities at primary and final timepoints vs pts from comparator groups. Conclusions: Across 4 Ph 3 studies, bari treatment improved workplace and daily activities in RA pts. References: Dougados et al. Ann Rheum Dis 2015; Genovese et al. Ann Rheum Dis 2015; Taylor et al. Arthritis Rheumatol 2015; Fleischmann et al. Arthritis Rheumatol 2015 Disclosure of Interest: J. Smolen Grant/research support from: AbbVie, Janssen, MSD, Pfizer, Roche, UCB, Consultant for: AbbVie, Amgen, Astra-Zeneca, Astro, Celgene, Glaxo, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB, A. DeLozier Employee of: Eli Lilly and Company, S. de Bono Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, L. Yang Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, C. Gaich Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company